Text Size
Santen Global

2023 IR News

RSS

IR News

Santen Announces Status of Share Buyback
Santen Receives European Commission Approval for Catiolanze® (cationic emulsion of latanoprost 50μg/mL) for Lowering of Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension
Santen Reports the 2nd Quarter Fiscal 2023 Consolidated Performance
Santen Announces Status of Share Buyback
Santen Announces Status of Share Buyback
Revision of Full-Year Earnings Forecasts
Santen Publishes its Annual Integrated Report “Santen Report 2023”
Notice Regarding Implementation of an Early Retirement Program
Santen Announces Status of Share Buyback
Santen Reports the 1st Quarter Fiscal 2023 Consolidated Performance
Santen Announces Status of Share Buyback
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration and Restricted Stock Unit Plans
Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America
Corporate Governance Report
Santen Announces Status of Share Buyback
Notice of Corporate Officer Changes
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration and Restricted Stock Unit Plans
Santen Announces Status of Share Buyback
Notice of Board of Director and Corporate Auditor Nominations
Santen Announces Share Buyback
Recording of Extraordinary Losses in Non-consolidated Financial Results
Santen Reports Fiscal 2022 Consolidated Performance
Revision of Full-Year Earnings Forecasts
Santen Announces New Medium-Term Management Plan (FY2023-FY2025)
Santen Files for Manufacturing and Marketing Approval for STN1011402 (Epinastine Hydrochloride) Ophthalmic Cream in Japan - Applied once daily to periocular area, new formulation for treatment of allergic conjunctivitis-
Santen Announces Completion of Share Buyback and Number of Shares to be Canceled
Santen Announces Cancellation of Treasury Shares
Notice of Corporate Officer Change
Santen Announces Status of Share Buyback
Santen Announces China NMPA Acceptance of STN1011101 Marketing Authorization Application in Patients with Open-Angle Glaucoma or Increased Intraocular Eye Pressure
Revision of Full-Year Earnings Forecasts
Santen Reports the 3rd Quarter Fiscal 2022 Consolidated Performance
Santen Announces Status of Share Buyback
Santen Announces Status of Share Buyback
 
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved